
Inhibikase Therapeutics IKT
€ 1.45
2.15%
Geschäftsbericht 2025
hinzugefügt 26.03.2026
Inhibikase Therapeutics Betriebsaufwand 2011-2026 | IKT
Betriebsaufwand Jährlich Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 3.52 M | 6.82 M | 6.16 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 6.82 M | 3.52 M | 5.5 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
12.8 B | $ 209.63 | -0.71 % | $ 371 B | ||
|
Verastem
VSTM
|
147 M | $ 4.99 | -5.77 % | $ 346 M | ||
|
VistaGen Therapeutics
VTGN
|
56.5 M | $ 0.57 | -5.85 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Voyager Therapeutics
VYGR
|
172 M | $ 3.96 | -4.24 % | $ 232 M | ||
|
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 12.36 | -11.46 % | $ 1.88 B | ||
|
Wave Life Sciences Ltd.
WVE
|
258 M | $ 6.39 | 3.06 % | $ 1.08 B | ||
|
Xenetic Biosciences
XBIO
|
5.81 M | $ 2.78 | -0.71 % | $ 4.73 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
XBiotech
XBIT
|
42.5 M | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xenon Pharmaceuticals
XENE
|
279 M | $ 54.44 | -1.96 % | $ 4.24 B | ||
|
Xeris Pharmaceuticals
XERS
|
94.7 M | $ 5.41 | -2.87 % | $ 868 M | ||
|
X4 Pharmaceuticals
XFOR
|
87.6 M | $ 4.07 | -5.57 % | $ 172 M | ||
|
Xencor
XNCR
|
303 M | $ 11.4 | -7.43 % | $ 846 M | ||
|
XOMA Corporation
XOMA
|
40.8 M | $ 29.93 | -1.97 % | $ 362 M | ||
|
22nd Century Group
XXII
|
8.43 M | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 1.06 | -2.75 % | $ 21.7 M | ||
|
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M |